North American Spine Society

Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago   

Retrieved on: 
Wednesday, October 12, 2022
Vestibular adenitis, LinkedIn, Innovation, Lipoma, Decompression, Ultrasound, Injury, Pelvis, Securities Act of 1933, Spine, Leiomyoma, NEXUS, Ovary, Inclusion, Failure, Surgeon, Cardiothoracic surgery, Evidence-based medicine, Twitter, Access, North American Spine Society, Company, Gastrointestinal tract, Orthopedic surgery, GLOBE, Uterine fibroid, Projection, Government, Growth, Review, Uterus, Research, Security (finance), NASS, Neurosurgery, Plastic and Reconstructive Surgery, Securities Exchange Act of 1934, MIS, U.S. Securities and Exchange Commission, General surgery, Sebaceous cyst, Terminology, Risk, Physician, Cedars-Sinai Medical Center, SEC, Patient, Nasdaq, Malignancy, Sex, Acquisition, Extremities, Forward-looking statement, COVID-19, Cardiac fibroma, Sebaceous gland, Bookbinding, Medical imaging, Gynaecology, MD

The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17.

Key Points: 
  • The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17.
  • The BoneScalpel Access handpiece allows surgeons to leverage the many advantages of ultrasonic bone cutting in minimally invasive spinal procedures.
  • Combined with OSTEOAMP Flowable, Bioventus now has a full portfolio for MIS spine procedures, the fastest growing segment of spine surgery.
  • The Bioventus surgical solutions portfolio brings together innovative products that add value for surgical applications in decompression and fusion.

Orthofix and MTF Biologics Recognized with 2022 Spine Technology Award for Virtuos Lyograft – a First-of-Its-Kind, Shelf-Stable and Complete Autograft Substitute for Spine and Orthopedic Procedures

Retrieved on: 
Wednesday, October 12, 2022
Biotechnology, Physical Therapy, Publishing, Surgery, General Health, Health, Medical Devices, Communications, Insurance, Elective surgery, Drug Quality and Security Act, Communication, Risk, SEC, Technology, Efficiency, Science, Organization, Â, NASDAQ, Annual report, Cell, Patient, Hospital, Carbon, Deutsches Institut für Bautechnik, NASS, Multimedia, Securities Act of 1933, Temperature, North American Spine Society, Publication, Company, International Institute of Refrigeration, Advanced Therapy Medicinal Product, German Institute for Medical Documentation and Information, Securities Exchange Act of 1934, Overalls, Dry ice, Terminology, MTF, Surgeon, Bookbinding, Pharmaceutical industry, Dentistry, Medical device, Orthopedic surgery, Spine, Virtuos

View the full release here: https://www.businesswire.com/news/home/20221012005256/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005256/en/
    Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute for use with spine and orthopedic procedures (Photo: Business Wire)
    The Virtuos Lyograft is a first-of-its-kind, shelf-stable and complete autograft substitute prepared by MTF Biologics through a proprietary process that preserves the biological components necessary for bone healing.
  • Additionally, Virtuos offers significant logistical and cost-saving advantages to the hospital with improved shipping, storage and operating room efficiency.
  • We are pleased to present Orthofix and MTF Biologics with the Best Technology in Spine award for the Virtuos Lyograft.
  • On behalf of our partner MTF Biologics and the team of dedicated employees at Orthofix, we are honored to receive this award, said Orthofix President of Global Spine Kevin Kenny.

New Partners Wenzel Spine and Safe group join Forces during NASS, National American Spine Society, between October 11 and 14th 2022

Retrieved on: 
Tuesday, October 11, 2022
CET, Hospital, Safe, Growth, Infection, Anatomy, Elective surgery, Patient, Fleurieux-sur-l'Arbresle, Surgeon, Entrepreneurship, NASS, Partnership, Technology, North American Spine Society, Spine, Marketing, 3D ultrasound, CEO, Patent, Safe Medical Device Amendments of 1990, Congress, MIS, CE, United Kingdom, FDA, National Center for Spinal Disorders, Solution, Medical device, Pharmaceutical industry

Safe Orthopaedics has already delivered stocking inventory of SteriSpine PS and SteriSpine VA to Wenzel Spine in order to start surgeries after the NASS congress.

Key Points: 
  • Safe Orthopaedics has already delivered stocking inventory of SteriSpine PS and SteriSpine VA to Wenzel Spine in order to start surgeries after the NASS congress.
  • Wenzel Spine received our inventory from Safe Orthopaedics earlier this week and we are ready to begin working with our partners through the expanded solutions that are immediately available., said William Wilson, Co-Founder and CEO of Wenzel Spine.
  • Pierre Dumouchel, Chairman and CEO of Safe Group, adds, The NASS congress is the perfect event to explain the benefits of our collaboration with Wenzel Spine.
  • Safe Medical, the medical device subcontractor for orthopaedic surgery of the group, will support the design of ready-to-use technologies and manufacturing of Wenzel Spine products.

Two-Year Clinical Data for DiscGenics's Progenitor Cell Therapy for Lumbar Disc Degeneration to Be Presented at NASS 2022

Retrieved on: 
Tuesday, October 11, 2022
Quality of life, Philippine Orthopedic Center, Strategic enrollment management, Central Time, National Primate Research Exhibition Hall, Patient, Back pain, Low back pain, NASS, Annual general meeting, Multimedia, MRI, North American Spine Society, Spine, Trial of the century, Company, SALT, MD, Convention, Chief commercial officer, Pain, Research, Adult, Safety, IDCT, Business development, Clinical trial, Communication, FDA, Pharmaceutical industry, Medical imaging

Dr. Gornet's presentation will take place on Wednesday, October 12 at 1:06PM Central Time during the Lumbar Degenerative Pathology Abstract Presentations in Room W471ab.

Key Points: 
  • Dr. Gornet's presentation will take place on Wednesday, October 12 at 1:06PM Central Time during the Lumbar Degenerative Pathology Abstract Presentations in Room W471ab.
  • DiscGenics is a sponsor of NASS 2022 and will host Booth# 5040 in the Exhibit Hall.
  • DiscGenics's first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, mild to moderate lumbar disc degeneration.
  • IDCT is a mixture of live Discogenic Cells, which are a unique progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier.

Surgalign™ Awarded 2022 Best New Technology Award from Orthopedics This Week for its HOLO Portal™ Surgical Guidance System

Retrieved on: 
Tuesday, October 11, 2022
Holo, LinkedIn, Physician, U.S. Securities and Exchange Commission, Engineering, SEC, Technology, Percussion section, Anatomy, AR, NASDAQ, Patient, Standard of care, Research, Twitter, McCormick, NASS, Orthopedic surgery, North American Spine Society, Spine, Solution, Company, Industry, AI, CEO, Wurmlingen, Food and Drug Administration, GLOBE, Forward-looking statement, Invention, Robotics, FDA, Â, Surgeon, Neurosurgery, Medicine, Medical device

The 2022 jury of senior spine and neurosurgeons voted Surgaligns HOLO Portal the Best New Technology of 2022.

Key Points: 
  • The 2022 jury of senior spine and neurosurgeons voted Surgaligns HOLO Portal the Best New Technology of 2022.
  • HOLO Portal is the worlds first surgical guidance system to incorporate AI and AR.
  • The HOLO Portal system uses AR to overlay the segmented AI reconstruction over the patients actual anatomy, providing real-time 3D visualization throughout the surgical procedure.
  • In January 2022, the Company received U.S. Food & Drug Administration (FDA) 510(k) clearance for use of the HOLO Portal system within lumbar spine procedures.

Aurora Spine Corporation to Attend the North American Spine Society (NASS) Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022
ASG, News, Silo, ZIP, Technology, Growth, Sacrum, Bone density, Education, Patient, Research, North American Spine Society, NASS, Risk, SI, Industry, TSX Venture Exchange, Spine, DEXA, GLOBE, McCormick Place, FDA, Booth, Solution, Ilium, ACDF, Risk management, Bristol & West Building Society v Ellis

CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it will be participating at the 2022 North American Spine Society (NASS) Annual Meeting, October 12-October 15, 2022 at McCormick Place West Building in Chicago, Illinois at Booth #4604.

Key Points: 
  • CARLSBAD, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced it will be participating at the 2022 North American Spine Society (NASS) Annual Meeting, October 12-October 15, 2022 at McCormick Place West Building in Chicago, Illinois at Booth #4604.
  • The North American Spine Society is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value and evidence-based spine care.
  • Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies.
  • Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release.

Aurora Spine Receives 2022 Best New Spine Technology Award for its DEXA bone density-matched spine implant innovation

Retrieved on: 
Tuesday, October 11, 2022
Aurora, ASG, News, Orthopedic surgery, Technology, Bone density, 3D, NASS, Solution, Spine, Publication, TSX Venture Exchange, CEO, DEXA, Patent, GLOBE, North American Spine Society, Surgeon, Risk, Dentistry, Bookbinding

Auroras DEXA Technology was recognized by RRY Publications LLC and the Orthopedics this Week magazine for its innovative technology developed to match spinal implants to patients bone density.

Key Points: 
  • Auroras DEXA Technology was recognized by RRY Publications LLC and the Orthopedics this Week magazine for its innovative technology developed to match spinal implants to patients bone density.
  • The award will be handed out at the 37th Annual Meeting of the North American Spine Society (NASS) inChicago,USA.
  • Aurora Spines first-of-its kind DEXA Technology is designed to match a patients bone density, promote bone in-growth while maintaining the biomechanical structure and bone support.
  • Aurora Spines DEXA Technology is part of the company's advanced portfolio representing the future of Spinal and Orthopedic implants.

Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting

Retrieved on: 
Tuesday, October 11, 2022
Traction, Month, Science, B cell, Magneto, Family, Patient, Injury, Back pain, Oracle Fusion Applications, Research, Surgeon, SIX Swiss Exchange, NASS, Kuros, CT, Solution, TGA, Company, Spine, Safety, Sustainable Development Technology Canada, FDA, Lehr, North American Spine Society, Veni, vidi, vici, Human, Medical imaging, Computer data storage, Pharmaceutical industry

Schlieren (Zurich), Switzerland, 11 October, 2022 Kuros Biosciences (Kuros or the Company), a leader in next generation bone graft technologies, announced today that it will present compelling clinical data on MagnetOs bone graft at the 38th Annual Meeting of the North American Spine Society (NASS), being held in Chicago October 12 to 15, 2022, in addition to completing a full commercial launch of MagnetOs Flex Matrix.

Key Points: 
  • Schlieren (Zurich), Switzerland, 11 October, 2022 Kuros Biosciences (Kuros or the Company), a leader in next generation bone graft technologies, announced today that it will present compelling clinical data on MagnetOs bone graft at the 38th Annual Meeting of the North American Spine Society (NASS), being held in Chicago October 12 to 15, 2022, in addition to completing a full commercial launch of MagnetOs Flex Matrix.
  • This first data, from the Companys five planned randomized controlled trials for MagnetOs, compares MagnetOs Granules to the gold standard of autograft bone.
  • The interim data exceed expectations for performance and validate MagnetOs as an augmented bone grafting option.
  • Details of the NASS presentations:
    t: +41 44 733 47 47t: +41 78 680 0538
    MagnetOs isn't like other bone grafts.

Orthofix Announces Presentation of Long-Term Evidence Highlighting the Clinical Management of Cervical Disc Arthroplasty at North American Spine Society Annual Meeting

Retrieved on: 
Monday, October 10, 2022
Biotechnology, FDA, Surgery, Health, Medical Supplies, Time, Insurance, Drug Quality and Security Act, Communication, Lessons learned, Risk, SEC, Hip, Kaplan–Meier estimator, Strathcona County, Degenerative disc disease, Annual report, NASDAQ, National Primate Research Exhibition Hall, Regulation of tobacco by the U.S. Food and Drug Administration, Patient, Hospital, Knee, NASS, Multimedia, Securities Act of 1933, Data, North American Spine Society, Spine, Food, Company, Convention, Securities Exchange Act of 1934, Red, Terminology, FDA, IDE, Surgeon, Medical device

(NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the presentation of long-term evidence highlighting the clinical management of cervical disc arthroplasty during the North American Spine Society (NASS) 2022 annual meeting October 12-15 in Chicago.

Key Points: 
  • (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the presentation of long-term evidence highlighting the clinical management of cervical disc arthroplasty during the North American Spine Society (NASS) 2022 annual meeting October 12-15 in Chicago.
  • View the full release here: https://www.businesswire.com/news/home/20221010005216/en/
    Orthofix M6-C Artificial Cervical Disc (Photo: Business Wire)
    We are pleased to sponsor the presentation of data supporting the clinical effectiveness of cervical disc arthroplasty including five-year data from our U.S. IDE study, said Kevin Kenny, Global President of Orthofix Spine.
  • We are honored to have a distinguished surgeon panel that will provide their insights about cervical disc replacement and long-term outcomes of this therapy for patients suffering from degenerative disc disease.
  • To learn more about the M6-C disc and the full portfolio of Orthofix solutions, please visit us at NASS at booth #2416.

LIMIFLEX™ IDE CLINICAL TRIAL INVESTIGATOR TO PRESENT POSITIVE FINDINGS AT THE NORTH AMERICAN SPINE SOCIETY ANNUAL MEETING

Retrieved on: 
Thursday, October 6, 2022
Tether, Quality of life, Spinal stenosis, SAN, Upstate University Hospital, Significance, Decompression, PMA, Population, US Foods, Patient, Spondylolisthesis, ADL, Research, Lordosis, NASS, Laminectomy, North American Spine Society, Spine, Disability, Orthopedic surgery, MD, Motion, ODI, Disease, CEO, Safety, Clinical trial, Sciatica, DST, Annual general meeting, FDA, IDE, Surgeon, Premarket tobacco application, Medical device, Bookbinding, Vaccine, Medical imaging

"These data indicate that LimiFlex DST is a promising alternative to fusion for this large patient population."

Key Points: 
  • "These data indicate that LimiFlex DST is a promising alternative to fusion for this large patient population."
  • The LimiFlex DST is the only device designed to restore the natural flexion stability of the lumbar spine.
  • The company is currently concluding a pivotal IDE trial in the U.S. For more information: https://www.limiflex.com/ .
  • Caution:The LimiFlex Dynamic Sagittal Tether is an investigational device in the United States and is limited by law to investigational use.